PARP Inhibitors: Staying on Target?

Craig L Doig; Gareth G Lavery

doi:10.1016/j.chembiol.2016.12.003

PARP Inhibitors: Staying on Target?

Craig L Doig, Gareth G Lavery

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

201 Downloads (Pure)

Abstract

Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.

Original language	English
Pages (from-to)	1442-1443
Number of pages	2
Journal	Cell Chemical Biology
Volume	23
Issue number	12
DOIs	https://doi.org/10.1016/j.chembiol.2016.12.003
Publication status	Published - 22 Dec 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chembiol.2016.12.003

Doig_et_al_PARP_inhibitors_Cell_Chemical_Biology_2016Accepted author manuscript, 416 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

@article{015bc3f4301243ae9e3b13bca85f57a0,

title = "PARP Inhibitors: Staying on Target?",

abstract = "Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.",

author = "Doig, {Craig L} and Lavery, {Gareth G}",

year = "2016",

month = dec,

day = "22",

doi = "10.1016/j.chembiol.2016.12.003",

language = "English",

volume = "23",

pages = "1442--1443",

journal = "Cell Chemical Biology",

issn = "2451-9448",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - PARP Inhibitors

T2 - Staying on Target?

AU - Doig, Craig L

AU - Lavery, Gareth G

PY - 2016/12/22

Y1 - 2016/12/22

N2 - Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.

AB - Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.

U2 - 10.1016/j.chembiol.2016.12.003

DO - 10.1016/j.chembiol.2016.12.003

M3 - Article

C2 - 28009975

SN - 2451-9448

VL - 23

SP - 1442

EP - 1443

JO - Cell Chemical Biology

JF - Cell Chemical Biology

IS - 12

ER -

PARP Inhibitors: Staying on Target?

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this